ABNX.PA Abionyx Pharma SA

Healthcare Biotechnology Euronext Paris
1.55 EUR
Close of Nov 7, 2026
1.41 4.53
Market cap
EUR 67.9M
P/E
-
P/B
4.30x
ROE
-122.8%
Dividend yield
-
Fundamental score
0.3/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ABNX.PA undervalued?

Graham number

The Graham number of Abionyx Pharma SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Abionyx Pharma SA fundamental analysis

1 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-48.22%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-41.49%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 0/2

The stock's high Price-to-Book Value (P/BV) ratio (4.66x) suggests it's overvalued, potentially making it an expensive investment.

DER 1/2

The stock maintains a fair debt to equity ratio (56%), indicating a reasonable balance between the money it owes and the ownership it possesses.

Revenue Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Net Profit Growth 0/2

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

Assets Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Graham Number 0/1

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

Dividend Growth 0/2

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Dividend 0/2

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Buffet Intrinsic Value 0/1

Based on Warren Buffett's formula, the company's stock seems overpriced (-1), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Abionyx Pharma SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Abionyx Pharma SA

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase …

Full company profile